{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:23:17Z","timestamp":1788992597060,"version":"build-2803163510"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Glucose monitoring is an important part of medical care in diabetes mellitus, which not only helps assess glycemic control and treatment safety, but also assists with treatment adjustment. With the development of continuous glucose monitoring (CGM), the use of CGM has increased rapidly. With the wealth of glucose data produced by CGM, new metrics are greatly needed to optimally evaluate glucose status and guide the treatment. One of the parameters that CGM provides, time in range (TIR), has been recognized as a key metric by the international consensus. Before the adoption of TIR in clinical practice, several issues including the minimum length of CGM use, the setting of the target range, and individualized TIR goals are summarized. Additionally, we discussed the mounting evidence supporting the association between TIR and diabetes-related outcomes. As a novel glucose metric, it is of interest to compare TIR with other conventional glucose markers such as glycated hemoglobin A1c. It is anticipated that the use of TIR may provide further information on the quality of glucose control and lead to improved diabetes management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002582","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T13:01:18Z","timestamp":1679317278000},"page":"522-527","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Research progress in the application of time in range: more than a percentage"],"prefix":"10.1097","volume":"136","author":[{"given":"Jintao","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"e3581","DOI":"10.1002\/dmrr.3581","article-title":"Clinical application guidelines for blood glucose monitoring in China (2022 edition)","volume":"38","author":"Bao","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1089\/dia.2017.0029","article-title":"Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters","volume":"19","author":"Wright","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc17-0636","article-title":"The fallacy of average: how using HbA(1c) alone to assess glycemic control can be misleading","volume":"40","author":"Beck","year":"2017","journal-title":"Diabetes Care"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R7-20250602","first-page":"1788","article-title":"The glycemic excursions in normal glucose tolerance individuals revealed by continuous glucose monitoring system (in Chinese)","volume":"84","author":"Yu","year":"2004","journal-title":"National Med J China"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1177\/193229680900300619","article-title":"Display of glucose distributions by date, time of day, and day of week: new and improved methods","volume":"3","author":"Rodbard","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"R11-20250602","first-page":"315","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) (in Chinese)","volume":"13","year":"2021","journal-title":"Chin J Diabetes Mellit"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s13300-021-01081-3","article-title":"Improvement in glucose regulation using a digital tracker and continuous glucose monitoring in healthy adults and those with type 2 diabetes","volume":"12","author":"Dehghani Zahedani","year":"2021","journal-title":"Diabetes Ther"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/dia.2021.0521","article-title":"Feasibility of closed-loop insulin delivery with a pregnancy-specific zone model predictive control algorithm","volume":"24","author":"Ozaslan","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(20)30367-9","article-title":"Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial","volume":"5","author":"Beardsall","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1620\/tjem.255.221","article-title":"The optimal \u201cTime in Range\u201d and \u201cTime below Range\u201d are difficult to coordinate in patients with type 1 diabetes","volume":"255","author":"Sekiguchi","year":"2021","journal-title":"Tohoku J Exp Med"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.2337\/dc20-0561","article-title":"Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy","volume":"43","author":"Lu","year":"2020","journal-title":"Diabetes Care"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc20-1862","article-title":"Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study","volume":"44","author":"Lu","year":"2021","journal-title":"Diabetes Care"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/dia.2019.0251","article-title":"Time in range is associated with carotid intima-media thickness in type 2 diabetes","volume":"22","author":"Lu","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20250602","first-page":"1061","article-title":"Association between time in range and diabetic retinopathy among patients with type 2 diabetes mellitus: a cohort study (in Chinese)","volume":"13","author":"Wang","year":"2021","journal-title":"Chin J Diabetes Mellit"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"e000991","DOI":"10.1136\/bmjdrc-2019-000991","article-title":"Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease","volume":"8","author":"Mayeda","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1097\/CM9.0000000000002140","article-title":"Relationship between time in range and corneal nerve fiber loss in asymptomatic patients with type 2 diabetes","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin Med J"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00125-019-4850-0","article-title":"Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies","volume":"62","author":"Kristensen","year":"2019","journal-title":"Diabetologia"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"e20171162","DOI":"10.1542\/peds.2017-1162","article-title":"Continuous glucose monitoring in very preterm infants: a randomized controlled trial","volume":"140","author":"Galderisi","year":"2017","journal-title":"Pediatrics"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2337\/dc20-1448","article-title":"Thresholds of glycemia and the outcomes of COVID-19 complicated with diabetes: a retrospective exploratory study using continuous glucose monitoring","volume":"44","author":"Shen","year":"2021","journal-title":"Diabetes Care"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jdi.13437","article-title":"Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol","volume":"12","author":"Ohigashi","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.diabres.2011.09.032","article-title":"Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects","volume":"95","author":"Januszewski","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.diabet.2017.10.005","article-title":"Glucose variability: do we have to revisit the profusion of definitions to avoid confusion?","volume":"44","author":"Monnier","year":"2018","journal-title":"Diabetes Metab"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"108032","DOI":"10.1016\/j.diabres.2020.108032","article-title":"Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: a preliminary study","volume":"161","author":"Lu","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"R33-20250602","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/dia.2019.0440","article-title":"Glucose time in range, time above range, and time below range depend on mean or median glucose or HbA1c, glucose coefficient of variation, and shape of the glucose distribution","volume":"22","author":"Rodbard","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrendo.2017.3","article-title":"Metrics for glycaemic control from HbA1c to continuous glucose monitoring","volume":"13","author":"Kovatchev","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/dia.2017.0416","article-title":"Metrics to evaluate quality of glycemic control: comparison of time in target, hypoglycemic, and hyperglycemic ranges with \u201crisk indices\u201d","volume":"20","author":"Rodbard","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1515\/cclm-2011-0853","article-title":"IFCC standardised HbA(1c): should the world be as one?","volume":"50","author":"John","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1479164118756240","article-title":"Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice","volume":"15","author":"Ajjan","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/dom.12907","article-title":"Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes","volume":"19","author":"Aberer","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-019-4946-6","article-title":"55(th) EASD Annual Meeting of the European association for the study of diabetes: Barcelona, Spain, 16-20 September 2019","volume":"62","year":"2019","journal-title":"Diabetologia"},{"issue":"(Suppl 1)","key":"R40-20250602","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1089\/dia.2009.0002","article-title":"A tale of two compartments: interstitial versus blood glucose monitoring","volume":"11","author":"Cengiz","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/dia.2017.0455","article-title":"Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control","volume":"20","author":"Riddlesworth","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/dia.2010.0156","article-title":"Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring","volume":"13","author":"Xing","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/dia.2020.0387","article-title":"Robust determination of the optimal continuous glucose monitoring length of intervention to evaluate long-term glycemic control","volume":"23","author":"Herrero","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/dom.14483","article-title":"Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time-in-ranges with the desired precision","volume":"23","author":"Camerlingo","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R45-20250602","first-page":"S432","article-title":"Continuous glucose monitoring: a longer sampling duration is required for optimal sampling of those with a higher baseline glucose variability","volume":"62","author":"Jacob","year":"2019","journal-title":"Diabetologia"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/pedi.13115","article-title":"Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: determination of optimal sampling duration","volume":"21","author":"Piona","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdi.13811","article-title":"Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients","volume":"13","author":"Wang","year":"2022","journal-title":"J Diabetes Investig"},{"key":"R48-20250602","first-page":"19322968221085273","article-title":"A Glycemia Risk Index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings","author":"Klonoff","year":"2022","journal-title":"J Diabetes Sci Technol"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1932296817718561","article-title":"The comprehensive glucose pentagon: a glucose-centric composite metric for assessing glycemic control in persons with diabetes","volume":"12","author":"Vigersky","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1932296814561288","article-title":"Obtaining reimbursement in France and Italy for new diabetes products","volume":"9","author":"Schaefer","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12902-019-0439-3","article-title":"Rationale and protocol for the Assessment of Impact of Real-time Continuous Glucose Monitoring on people presenting with severe Hypoglycaemia (AIR-CGM) study","volume":"19","author":"Avari","year":"2019","journal-title":"BMC Endocr Disord"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:08:25Z","timestamp":1748905705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002582","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]}}}